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Abstract 
Background: Previous work with 3‑week hydrocephalic rats showed that white matter damage could be reduced by 
the calcium channel antagonist magnesium sulfate (MgSO4). We hypothesized that MgSO4 therapy would improve 
outcomes in ferrets with hydrocephalus induced with kaolin at 15 days.
Methods: MRI was performed at 29 days to assess ventricle size and stratify ferrets to treatment conditions. Begin‑
ning at 31 days age, they were treated daily for 14 days with MgSO4 (9 mM/kg/day) or sham saline therapy, and then 
imaged again before sacrifice. Behavior was examined thrice weekly. Histological and biochemical ELISA and myelin 
enzyme activity assays were performed at 46 days age.
Results: Hydrocephalic ferrets exhibited some differences in weight and behavior between treatment groups. Those 
receiving MgSO4 weighed less, were more lethargic, and displayed reduced activity compared to those receiving 
saline injections. Hydrocephalic ferrets developed ventriculomegaly, which was not modified by MgSO4 treatment. 
Histological examination showed destruction of periventricular white matter. Glial fibrillary acidic protein content, 
myelin basic protein content, and myelin enzyme activity did not differ significantly between treatment groups.
Conclusion: The hydrocephalus‑associated disturbances in juvenile ferret brains are not ameliorated by MgSO4 treat‑
ment, and lethargy is a significant side effect.
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Background
Hydrocephalus is a common neurological condition 
where cerebrospinal fluid (CSF) flow dynamics are 
altered, leading to enlargement of ventricular cavi-
ties in the brain. The histopathologic consequences of 
hydrocephalus depend on the age of onset, rate of ven-
tricular enlargement, and the etiology [1]. The brain 
damage induced by hydrocephalus is multifactorial with 
mechanical factors leading to primary destruction of 
periventricular axons due to gradual physical stretching 
and compression, accumulation of metabolic waste prod-
ucts in the CSF, and ischemic changes causing decreased 
white matter blood flow that contributes to axonal and 
oligodendroglial damage [2, 3]. Elevated calcium (Ca2+) 
coincides with increased white matter content of calpain 
I, along with heightened immunoreactivity in periven-
tricular axons exhibited by young hydrocephalic rats with 
appreciable axonal damage, which suggest that calcium-
mediated proteolysis may be associated with axonal 
cytoskeletal damage found in hydrocephalus [4].
Magnesium (Mg2+) is a calcium channel antagonist; 
extracellular Mg2+ antagonizes Ca2+ influx by blocking 
voltage and receptor-mediated calcium channels along 
with NMDA channel receptors in a voltage-dependent 
manner [5, 6]. Intracellular Mg2+ is regulated by at least 
five distinct transporters [7]. Peripherally administered 
Mg2+ enters brain tissue of rabbits and cats, albeit to a 
lesser magnitude than muscle [8]. Magnesium sulfate 
(MgSO4) administration by bolus or short-term infusion 
(e.g. 3  days) has shown short-term (hours to <7  days) 
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outcome improvements in animal models of experi-
mental spinal cord injury [9], reversible focal cerebral 
ischemia [10], kainate induced neuron degeneration [11], 
hypoxic-ischemic brain damage [12, 13], and traumatic 
brain injury [14–16]. Few experiments have looked at 
longer-term benefits of magnesium. A bolus of magne-
sium chloride after fluid percussion brain injury in adult 
rats was associated with improved motor outcome at 
4 weeks [17].
Clinically, MgSO4 has been used to suppress uterine 
contractions during premature labor and to reduce con-
vulsions in pregnant women with preeclampsia [18]. In 
these circumstances, there is an association between 
maternal receipt of MgSO4 and reduced risk of cere-
bral palsy in the offspring; this suggests that it could be 
neuroprotective in preterm birth although the benefit 
in term birth is much less clear [19, 20]. In infants with 
hypoxic-ischemic encephalopathy, the composite results 
of five clinical trials indicate a significant reduction in the 
unfavorable short-term outcome but a trend to increased 
mortality overall [21]. If effective, its protective mecha-
nism remains unclear. MgSO4 is a vasodilator that might 
improve cerebral circulation [22]. It can also reduce 
monocyte-mediated proinflammatory cytokine produc-
tion and increase intracellular magnesium levels, which 
may be beneficial in decreasing inflammation [23].
Pharmacologic intervention might be a useful supple-
ment to surgical shunts for the management of hydro-
cephalus [24]. We previously showed that MgSO4 was 
beneficial in hydrocephalic rats [25]. Three-week old 
rats received kaolin injections into the cisterna magna to 
induce hydrocephalus; after 2  weeks, they were treated 
with parenteral administration of MgSO4 for 2 more 
weeks. There was reduced reactive astrogliosis in the 
frontal cerebrum and improved gait performance on an 
accelerating rotating cylinder task. Despite these ben-
efits, research with rodents is limiting because they have 
a small volume of white matter, which is the main region 
of damage in human brains. Moreover, stroke research 
has provided a valuable lesson in the major setbacks that 
can occur when basing clinical treatment on the suc-
cess of pharmacological studies with rodents; this has 
prompted the necessity of preclinical treatment efficacy 
in gyrencephalic brains before proceeding to human tri-
als [26]. Thus, we developed a model of hydrocephalus in 
2-week old ferrets using injection of kaolin (aluminum 
silicate) into the cisterna magna, and we showed simi-
larities to other animal models and the human condition 
[27]. Ferrets are born with relatively immature brains 
which develop a complex gyrencephalic morphology 
that has been studied extensively [28, 29]; consequently 
they are useful for modeling the neurologic disorders 
of human fetuses and infants [30]. Our overall goal is to 
develop a pharmacologic intervention that could be used 
to mitigate brain damage in the period prior to definitive 
shunt therapy. We hypothesized that MgSO4 treatment 
would lead to behavioral, structural, and/or biochemical 




Twenty pigmented sable ferret kits (n  =  13 males and 
n  =  7 females) were obtained from Marshall Farms 
(North Rose, NY) at postnatal day 7 (P7) in 4 l along with 
their mothers (jills). The kits stayed with their moth-
ers in enclosed cages until P46. The cages were located 
in a room kept on a 12:12  h (6 a.m.–6 p.m.) light–dark 
cycle, and the room temperature and relative humid-
ity were 21–22 °C and ~35–45 %, respectively. Food and 
water were provided ad  libitum; the kits started eat-
ing solid food around P30. For identification, tattoos 
were imprinted on their paws. All animals were treated 
humanely according to the guidelines set forth by the 
Canadian Council on Animal Care. The institutional 
animal ethics committee approved the experimental 
protocols (protocol #11-012). All efforts were made to 
minimize the number of animals used and ensure the 
least amount of suffering experienced.
Hydrocephalus induction
Hydrocephalus was induced using kaolin (aluminum sili-
cate; Sigma, St. Louis MO) as described previously [27]. 
Briefly, kaolin injections were performed on all 4 litters 
at P15 (5 per litter—total n = 20; weight 69–93 g). They 
were anesthetized using 2.5 % isoflurane in oxygen, and 
the dorsum of their necks were shaved and cleansed. 
Using a 27-gauge needle, 0.2  mL of 20  % sterile kaolin 
suspension (250  mg/mL in 0.9  % saline) was injected 
percutaneously into the cisterna magna under aseptic 
conditions. Animals were monitored during recovery 
and observed for signs of discomfort and/or neurologi-
cal impairment and then were otherwise returned to 
their mothers. Subcutaneous (sc) injections of buprenor-
phine (0.03  mg/kg) and sterile 0.45  % saline were given 
every 12 h for 2 days to decrease potential pain and pos-
sible dehydration, respectively. They were weighed daily, 
and those experiencing severe neurologic impairment or 
weight loss were sacrificed to cease further suffering.
Magnetic resonance imaging and assignment to treatment 
groups
The T2-weighted MR images of the brain were obtained 
using with a 7 Tesla Bruker Biospec/3 MR scanner 
(Karlsruhe, Germany) as previously described [27]. The 
first images were attained 2 days post kaolin injections at 
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P17 to confirm successful hydrocephalus induction with 
kaolin, and then 14  days post kaolin at P29 to examine 
ventricle size and stratify treatment groups. The areas 
of the lateral ventricles to cerebrum brain area, third 
ventricle width to cerebrum width, cerebral aqueduct 
area to midbrain area, and fourth ventricle area to hind-
brain area ratios were measured as previously described 
[27]. Ferrets were stratified based on ventricle size and 
assigned listwise to saline (0.9 % NaCl) and MgSO4 treat-
ment groups. A third set of MR images was taken after 
the 14-day drug treatment period at P45, no more than 
24 h before euthanasia, to assess ventricle size again.
Drug preparation and administration
The MgSO4 and/or NaCl treatments were administered 
starting 16  days post-kaolin at P31 (n  =  8 for MgSO4 
and n  =  8 for NaCl). All animals were weighed daily, 
and their weights were used to calculate treatment vol-
umes. Stock solutions of 1.0 M MgSO4 and 0.9 M NaCl 
were prepared in distilled H2O at room temperature and 
stored at 4  °C; the solutions were labeled A and B, and 
treatments were given blindly based upon a volume drug 
to body weight formula. They received either a ~9 mM/
kg/day dosage of MgSO4 or NaCl daily for 14 days, which 
were administered by sc injections given 3 times per day 
on weekdays (~3  mM/kg/dose) and 2 times per day on 
weekends (~4.5 mM/kg/dose) to ensure that all animals 
received the entire dosage. This calculated dosage was 
derived from testing different MgSO4 concentrations 
with rodents in a previous study, where 8.2 mM/kg/day 
was found to be protective [25]. The ferrets received their 
first injection in the morning before behavioral testing. 
Their second daily injection was given in the late after-
noon, and the third injection was administered near mid-
night to maintain trough levels. Because of the expense, 
we could not conduct a dose-escalation study.
Behavioral testing
Previous work with kaolin-induced hydrocephalic fer-
rets [27] showed that they differed from controls in a 
limited number of the behavioral tests previously studied 
[31]; these were chosen for the current study. Behavio-
ral testing commenced at P10-11 and continued 3 times 
weekly until P43-44 for all kits (n =  16). Behavior tests 
were conducted prior to the daily drug administration 
to minimize the effect of lethargy in the MgSO4 recipi-
ents. The kits were not exposed to the test situations 
prior to testing. Open field behavior was assessed using 
two apparatuses. The first chamber was an enclosed 
square (44  ×  43  ×  29  cm) with 15 light beam sensors 
on each axis to quantitate ambulatory, vertical, and total 
movements (Opto-Varimex 3; Columbus Instruments 
International Corp., Columbus, OH, USA). Animals were 
observed individually for 3 min and tested once per ses-
sion. The second chamber was a 75 × 75 × 45 cm trans-
parent plastic square, where the kits were videotaped, 
and motor performance was analyzed for 3  min using 
HVS Image  2100 Plus Tracking System software (HVS 
Image Ltd, Twickenham, Middlesex, UK). Quantitative 
measures were performed after dividing the chamber 
into 100 (7.5 × 7.5 cm) squares and included the length 
of path traversed and the number and percent of squares 
entered. Qualitative observations were also recorded in 
the second chamber for pivoting, crawling, walking, run-
ning, and rearing.
Sacrifice and brain dissection
Ferrets were euthanized within 24  h of final MRI using 
isoflurane anesthesia (5  %) followed by carbon dioxide 
(CO2) narcosis and exsanguination by transcardiac per-
fusion at ~P46 or when humane endpoints were met as 
described previously [27]. Ferret brains were rapidly 
removed, photographed, and then split in the parasagit-
tal plane 1 mm from the midline. The right hemisphere 
was dissected into anterior frontal lobe, dorsal frontal 
cerebrum, and dorsal parietal cerebrum, which were fro-
zen in liquid nitrogen (N2) and stored at −70 °C. The left 
hemisphere was immersion fixed in cold 3  % buffered 
paraformaldehyde for several days; then it was sliced in 
the coronal plane, dehydrated, and embedded in paraffin 
wax.
Histology and immunohistochemistry
All paraffin blocks were sectioned coronally (6 μm thick-
ness) and stained with hematoxylin and eosin (H and 
E). The cerebrum at the level of the anterior horn of the 
lateral ventricles was stained with solochrome cyanine 
and counterstained with eosin for visualization of mye-
lin. Sections were immunostained with rabbit polyclonal 
anti-glial fibrillary acidic protein (GFAP; 1:10,000 dilu-
tion; DAKO Z0334; Glostrup, Denmark) to label astro-
cytes and reactive astrocytes. The primary antibody 
underwent 1.5  h incubation at room temperature. This 
was followed by incubation with appropriate biotinylated 
secondary antibody, followed by reaction with streptavi-
din-peroxidase, detection with diaminobenzidine (DAB, 
Sigma D5905), and finally counterstaining with hematox-
ylin. Negative controls were treated without the primary 
antibody. Corpus callosum thickness was measured using 
100× ocular magnification at the sagittal midline and 
above the lateral angle of the anterior horn of the lateral 
ventricle. The second site was chosen because fragmenta-
tion of the midline region in some hydrocephalic brains 
preventing proper measurement of corpus callosum 
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thickness. For comparative purposes, non-hydrocephalic 
ferrets from our previous experiment [27] were also 
examined.
Myelin enzymes and enzyme‑linked immunosorbent 
assays
Frozen dorsal frontal and parietal cerebrum samples 
were homogenized using a radio immunoprecipitation 
assay (RIPA) buffer including protease inhibitors phe-
nylmethylsulfonyl fluoride (PMSF) and aprotinin, which 
likely explain the lower myelin enzyme activities than 
were obtained previously [27]. Total protein quantifica-
tion was determined with the Micro BCA (Pierce) Pro-
tein Assay kit (Thermo Scientific, Rockford, Illinois, 
USA). Dorsal frontal cerebrum homogenates were used 
to quantify myelin basic protein (MBP) and GFAP con-
tent by using ELISAs, as previously described in detail 
[27]. Colorimetric assays were performed in triplicate, 
and results are shown in μg of MBP or GFAP per gram 
of protein and averaged per sample. Dorsal parietal cer-
ebrum samples were used to quantify the enzyme activ-
ity of UDP-galactose:ceramide galactosyltransferase 
(CGalT) and glycerylphosphorylcholine phosphocholine 
phosphodiesterase (GPC-PP) using the artificial sub-
strate p-nitrophenylphosphorylcholine (pNPP). Both are 
enzymes that are enriched in myelin. They were quanti-
fied in triplicate as described previously [32, 33].
Atomic absorption spectroscopy
Flame atomic absorption spectroscopy (FAAS) was per-
formed to determine Mg levels in anterior forebrain 
samples as indicated previously [34] except for the fol-
lowing differences. Ferrets were given their last dose of 
MgSO4 or NaCl 35–152 min (mean 68.88 ± 13.46) before 
sacrifice. Forebrain samples were thawed and weighed 
then dissolved in 18  M sulfuric acid and 16  M nitric 
acid over gentle heat. Standards were prepared from a 
1000 μg mL−1 Mg standard solution (Alfa Aesar 88077) at 
concentrations of 0.50, 0.40, and 0.20 μg mL−1, along with 
a 1 % nitric acid blank. Mg content was measured using 
Atomic Absorption Spectrometer AAnalyst 400 with a 
PerkinElmer Lamp (Intensitron) using a wavelength of 
285.21  nm. Measurements were performed in triplicate 
and averaged to obtain concentrations (μg  Mg2+ per 
gram brain tissue).
Statistical analysis
All data are presented as mean ± SEM, unless otherwise 
indicated. Quantitative data were analyzed to confirm 
a normal distribution, and p values ≤0.05 were con-
sidered statistically significant. Statistical analyses for 
the behavioral tasks, MRI, and all biochemical analyses 
were conducted with the juvenile ferrets (n =  15). Data 
were assessed using ANOVA and two-tailed t-tests for 
behavioral testing, ventricle size, histological data, and 
biochemical assays to compare MgSO4 and NaCl hydro-
cephalic treatment groups. Qualitative assessments for 
motor and behavioral development were analyzed sepa-
rately from quantitative measures. Statistical analyses 
were conducted using the SPSS 19.0 software program.
Results
Mortality
Of the 20 kaolin-injected juvenile ferrets, three were 
euthanized due to severe neurological deficits within the 
first 2 days post-injection (P16), one was euthanized on 
P22 due to severe weight loss and neurological impair-
ment, and one was euthanized on P43 due to persistently 
low weight and neurological impairment despite only 
slight ventricle enlargement (this animal was initially 
assigned to receive MgSO4). Two of the remaining fer-
rets were nonhydrocephalic; these were used for com-
parative purposes only. The focus of the results is on the 
hydrocephalic ferrets (n = 13; 8 males and 5 females) that 
survived the 14-day drug therapy period. All were eutha-
nized within 24 h of the final MRI between postnatal days 
P45–P46.
Ventricle size on magnetic resonance imaging
Ventricular expansion was noticeable 2  days after kao-
lin injections, where the lateral ventricles were already 
significantly larger compared to the nonhydrocephalic 
animals (p  <  0.010, t test). From this time onward, the 
hydrocephalic ferrets displayed enhanced signal in the 
periventricular white matter on the T2-weighted MR 
images indicating elevated water content. At 14  days 
post-kaolin injections (P29), MR images showed a range 
of ventriculomegaly in the hydrocephalic ferrets (Fig. 1). 
This was particularly evident in the lateral and third ven-
tricles, which were significantly enlarged (both p < 0.05, 
t tests). Ferrets were stratified according to ventricle 
size and alternately assigned to MgSO4 or NaCl treat-
ment groups to ensure that there was no significant dif-
ference between hydrocephalic groups before therapy. 
Both hydrocephalic groups displayed further expansion 
of the ventricles during the therapeutic period, exhibiting 
significant progressive enlargement of the lateral (Fig. 2; 
Table 1) and third ventricles (all p < 0.05, t tests). Com-
parison of the NaCl- and MgSO4-treated ferrets showed 
no significant differences for any of the ventricle regions 
(all p > 0.05, t tests; Table 1).
Body weight and behavioral assessments
Behavioral testing began at P10–11 to determine base-
line performance before kaolin injection was performed 
at P15. Successful induction of hydrocephalus was 
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typically associated with weight loss for several days 
following injection. Overall, the hydrocephalic ferrets 
weighed 39 % less than nonhydrocephalic ferrets at P21 
(p < 0.001, t test) and 25 % less at P28 (p = 0.009, t test). 
After the 14-day treatment period, the MgSO4-treated 
hydrocephalic ferrets weighed significantly less than the 
NaCl hydrocephalic group during and after treatment (all 
p < 0.05, ANOVA; Table 1).
By the end of the pretreatment period (P28–P30), all 
the ferrets were crawling, similar to previously assessed 
motor development [27]. Walking commenced on P34–
37, with no appreciable differences between hydroce-
phalic groups. Qualitatively, both groups reached motor 
and behavioral developmental milestones at the same 
time, although several of the MgSO4-treated hydroce-
phalic ferrets (n =  5) were more unsteady and engaged 
in less exploratory behavior. Unlike our previous finding 
[27], the hydrocephalic ferrets did not become hyperac-
tive or wander in circles within the enclosure. MgSO4-
treated ferrets were more lethargic than NaCl-treated 
animals. Quantitative activity measurements showed 
that the hydrocephalic MgSO4 group displayed signifi-
cantly less ambulatory movement, fewer cell entries, 
less distance traveled overall, and less supported rear-
ing, compared to the NaCl group during the first week of 
treatment (all p < 0.05, ANOVA; data not shown). These 
between-group discrepancies were evident primarily 
during transition to walking phase of development but 
dissipated by the last behavioral time point measured and 
were not significantly different post-treatment (Table 1).
Structural and biochemical changes in brain
Macrophages that had engulfed kaolin and associated col-
lagen deposition were microscopically identified through-
out the basal subarachnoid space, having spread from 
the cisterna magna injection site; only rare macrophages 
were present in the fourth ventricle. Ventriculomegaly 
was accompanied by cerebral thinning surrounding the 
lateral ventricles and decreased depth of cerebral sulci. 
Intact white matter structures such as the internal cap-
sule showed equivalent myelin staining in hydrocephalic 
and non-hydrocephalic ferrets. There was thinning and 
fraying of the periventricular white matter in all hydroce-
phalic ferrets; these damaged regions had no myelin stain-
ing. The corpus callosum thickness did not differ between 
the MgSO4 and NaCl treatment groups (Fig. 3; Table 1). 
In comparison to non-hydrocephalic ferrets, there was a 
slight but not statistically significant reduction of cerebral 
MBP content in the hydrocephalic ferrets; however, there 
was no difference between treatment groups (Table  1). 
To determine if the severity of ventriculomegaly had any 
Fig. 1 T2‑weighted magnetic resonance images showing frontal 
coronal slices of brains of ferrets without hydrocephalus as well as 
ferrets that were treated with MgSO4 or NaCl between 29 and 45 days 
age. Progressive ventriculomegaly is evident in these examples of 
both treatments
Fig. 2 Box plots (mean ± standard error of mean) showing cross 
sectional ratio of the lateral ventricle frontal horn areas to the 
cerebrum on the magnetic resonance images. The 16‑day images 
were obtained 2 days after kaolin injection, the 29‑day images were 
14 days after kaolin injection and immediately prior to onset of drug 
treatment, and the 45‑day images were obtained at the end of the 
treatment period shortly prior to termination (n = 7 for NaCl and 
n = 6 for MgSO4 each at all time points). In comparison to non‑
hydrocephalic controls (not shown) and previous time points the 
ventricles enlarged progressively at successive time points (p < 0.05). 
There were no significant differences between the MgSO4 and NaCl 
treatment groups
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impact on the MBP content, both treatment groups were 
subdivided into moderate and severe hydrocephalus. Sub-
group analyses of the 4 most severely affected ferrets in 
each group showed no significant differences between 
groups (data not shown). It should be noted that the MBP 
content at P46 is just beginning the rapid accumulation 
phase [27]; this is comparable to human brain shortly 
after full term gestation.
In periventricular and perivascular foci of the white 
matter adjacent to the frontal horns of the lateral ven-
tricles, NaCl and MgSO4-treated hydrocephalic ferrets 
displayed similar GFAP immunostaining of hypertrophic 
astrocytes (Fig. 3). ELISA analysis of GFAP content was 
27 % lower in the MgSO4 hydrocephalic group compared 
to NaCl group, but the difference was not statistically sig-
nificant (p = 0.375, ANOVA; Table 1). Subgroup analysis 
of the most severely affected ferrets also did not reveal 
significant differences in GFAP content between treat-
ment groups (data not shown).
Myelin enzyme activity was measured in hydrocephalic 
ferret brains. CGalT is active in oligodendrocytes during 
myelin production [35]; we previously showed highest 
activity from P35–P56 [27]. There were no significant 
differences between hydrocephalic treatment groups 
(Table 1). GPC-PP is abundant in mature myelin [36]; we 
previously showed that the activity began to increase at 
P35 [27]. Compared to the untreated hydrocephalic fer-
rets, the MgSO4 group tended to show lower GPC-PP 
activity than the NaCl group (p =  0.056) (Table  1), but 
subgroup analysis still did not reach significance (data 
not shown).
Mg2+ in anterior forebrain samples was slightly, but not 
significantly, higher in the MgSO4 group compared to the 
NaCl-treated group (p = 0.38, t test) (Table 1).
Discussion
Mg2+ was shown to have mild protective benefits in 
rats with experimental hydrocephalus treated from 5 to 
7 weeks age but not in rats treated from 1 to 3 weeks age 
[25, 34]. We had hoped that MgSO4 treatment would also 
yield therapeutic benefits in young hydrocephalic fer-
rets. As has been recommended for preclinical stroke 
and brain trauma studies [26, 37], the experimental 
design included randomization, blinding, and multiple 
Table 1 Results of magnesium sulfate treatment on hydrocephalic ferrets
All data are presented as mean ± SEM. Behavior and ventricle size are specified at by postnatal day (P) age. All brain structural and biochemical data are at P46
CGalT ceramide galactosyltransferase
GFAP glial fibrillary acidic protein
GPC-PP glycerylphosphorylcholine phosphocholine phosphodiesterase
MBP myelin basic protein
* p < 0.05 control vs. hydrocephalic, t tests or ANOVA
@  p < 0.05 NaCl vs. MgSO4-treated ferrets, t tests or ANOVA







Sample size 2 7 6
Lateral ventricle area index (P29/pre‑treat) 0.012 ± 0.002 0.147 ± 0.024* 0.155 ± 0.023*
Lateral ventricle area index (P45/post‑treat) 0.006 ± 0.0005 0.219 ± 0.053*# 0.254 ± 0.046*#
Percent enlargement ventricles during treatment – 48.9 ± 23.1 63.9 ± 24.4
Body weight (g) (P29/pre‑treat) 148.0 ± 8.0 114.3 ± 4.8* 106.8 ± 9.1*
Body weight (g) (P45/post‑treat) 264.5 ± 34.5# 288.3 ± 12.8# 170.0 ± 31.0*@#
Rearing activity (beam breaks per 3 min) (P43/post‑treat) 71 ± 16 57 ± 15 22 ± 20*
Ambulatory activity (beam breaks per 3 min) (P43/post‑treat) 541 ± 21 460 ± 44 321 ± 71*
Total activity (beam breaks per 3 min) (P43/post‑treat) 684 ± 20 584 ± 54 443 ± 89*
Number cells entered—open field (per 3 min) (P43/post‑treat) 88 ± 7 115 ± 12 111 ± 15
Distance traveled—open field (m per 3 min) (P43/post‑treat) 5.64 ± 0.39 7.58 ± 0.95 7.11 ± 1.08
Medial corpus callosum thickness (μm) 965 ± 95 410 ± 71* 315 ± 97*
Lateral corpus callosum thickness (μm) 665 ± 45 330 ± 50* 245 ± 59*
MBP content frontal cerebrum (μg MBP/g protein) 72.19 ± 12.75 64.25 ± 19.66 56.07 ± 14.15
CGalT activity parietal cerebrum (nM/mg protein/h) 0.029 ± 0.008 0.075 ± 0.024 0.051 ± 0.014
GPC‑PP activity parietal cerebrum (nM/mg protein/h) 15.25 ± 1.83 14.42 ± 0.90 11.64 ± 1.20
GFAP content frontal cerebrum (μg GFAP/g protein) 0.64 ± 0.02 0.90 ± 0.13 0.70 ± 0.12
Frontal cerebrum magnesium (μg Mg2+/g brain tissue) 133.64 ± 4.97 135.59 ± 10.37 150.89 ± 5.23
Page 7 of 9Di Curzio et al. Fluids Barriers CNS  (2016) 13:7 
outcome measures. However, in comparison to NaCl-
treated hydrocephalic ferrets, we did not find any behav-
ioral, histological, or biochemical evidence to support 
the hypothesis that MgSO4 therapy, at the same dose 
that was effective in rats, benefits hydrocephalic ferrets. 
Treated ferrets had transient sedation, which is well-
documented [38], impaired weight gain, and tendency to 
greater progression of ventriculomegaly. Despite more 
severely enlarged ventricles, MgSO4 treatment was asso-
ciated with reduced GFAP accumulation in ferrets albeit 
not significantly; this finding is similar to that seen in 
hydrocephalic rats treated from 5 to 7  weeks age [25]. 
Reduced astroglial reaction has also been reported in 
kaolin-induced and congenitally hydrocephalic H-Tx rats 
treated with minocycline or decorin [39–41]. Although 
reduced GFAP accumulation is often considered an indi-
cator of benefit, another possibility is that Mg2+, which 
blocks signaling between astrocytes [42], simply masks 
the astrocytic response to brain damage.
Why was MgSO4 therapy unsuccessful in hydrocephalic 
ferrets? Rationale for the experiment was based upon a 
previously-demonstrated neuroprotective effect in juve-
nile hydrocephalic rats and a range of experimental data 
from other neurological disorders. Technical and design 
aspects must be considered. It remains unclear whether 
entry of Mg2+ into brain is via the choroid plexus and 
CSF or through the blood brain barrier [43, 44], although 
the observed side effect of sedation indicates entry into 
the brain [8, 45, 46]. Lethargy is a potential confounder 
in the behavioral assessments, and it prevented complete 
blinding of the investigators. More importantly, weight 
gain was retarded in the MgSO4 treated ferrets, possi-
bly because lethargy impaired feeding or because of the 
effect of Mg2+ on intestinal smooth muscle [7]. Under-
nutrition might have had a negative effect on the out-
come. This might be overcome experimentally by using 
a matched feeding strategy. Unfortunately, ferrets are 
obligate carnivores with short intestinal tracts; they can 
require special diets when they are ill [47], and therefore 
might not be the ideal animal for studies where feeding 
is compromised. Periodic subcutaneous injections would 
result in troughs and peaks; in rats Mg2+ levels peak at 
approximately 2 h and return to normal levels within 4 h 
after injection [25]. We had considered using osmotic 
minipumps, but none would accommodate sufficiently 
large volumes for the treatment period nor could they 
adjust for the increasing weight of the maturing ferrets. 
Furthermore, based on discussions with the veterinar-
ians, the potential complications (maternal biting of 
the surgical site and sloughing of the skin over the min-
ipumps) outweighed the potential benefits. During the 
treatment period, we did observe that the MgSO4-treated 
ferrets experienced some skin irritation at the injection 
sites; rotating the locations of the injections minimized 
this. Oral administration potentially provides longer peri-
ods of exposure; however, peak levels are not as high as 
those that follow parenteral administration [48]. We also 
observed that some MgSO4-treated ferrets began gag-
ging and/or vomiting immediately after injections, which 
would have made repeated gavage difficult. In a clinical 
situation, tube feeding would negate this confounder. 
Perhaps the intervention was timed incorrectly. If the 
ventricular enlargement is too mild a therapeutic benefit 
might be difficult to detect or if the intervention is too 
late, no benefit might be possible. However, subgroup 
analysis of the 4 most severely affected ferrets in each 
group as well as the least severely affected still showed no 
significant differences between treatment groups.
We must also consider that the rodent experimental 
studies considered in the Introduction do not translate 
to larger animals. The majority documented only short-
term benefit. In short term studies of brain hypoxic-
ischemic damage in immature rat, sheep, and pig models, 
MgSO4 has had inconsistent outcomes and results have 
been confounded by mild hypothermia; for this condition 
reviewers concluded “peripherally administered MgSO4 
is unlikely to be neuroprotective” [49]. A meta-analysis of 
Fig. 3 Photomicrographs showing white matter above the frontal 
horn of the lateral ventricle in 46‑day‑old hydrocephalic ferret brains, 
after a 14‑day treatment period with MgSO4 or NaCl. a (upper pair)—
corpus callosum CC thinning is evident in both animals (solochrome 
cyanine stains myelin blue, with pink eosin counterstain). b (lower 
pair)—GFAP immunolabeling (brown) showing hypertrophic reactive 
astrocytes in periventricular white matter near the lateral angle of the 
frontal horn. There is no obvious difference between the two groups 
of hydrocephalic ferrets. Objective magnification: a‑40x, b‑100x; Scale 
bar = 100 μm. Lateral ventricles LV, Subventricular zone SVZ
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8 randomized controlled trials with a total of 786 head-
injured patients indicates that MgSO4 has no signifi-
cant improvement for mortality, but there is borderline 
improvement in the glasgow outcome scale [50].
Conclusion
Young hydrocephalic ferrets at the age during which cer-
ebral myelin production is just beginning did not exhibit 
behavioral benefits or white matter protection from 
MgSO4 therapy. Although MgSO4 seems to be safe in 
other situations, it was associated with severe sedation, 
which can compromise feeding. Considering the experi-
mental and epidemiologic evidence that Mg2+ might 
protect the developing brain in other diseases, this nega-
tive result should not completely exclude its possible 
benefits in hydrocephalus. However, preclinical testing 
might have to be done in a larger animal model wherein 
continuous delivery is possible or more control can be 
achieved over feeding. We will continue to explore other 
pharmacological agents that can be used as a supplement 
to shunt treatment of hydrocephalus in gyrencephalic 
animal models.
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